Clinical trials: injection or injectable or infusion or IV or syringe or subcutaneous
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Funder type Industry (pharma, biotech, devices)
Chronic Graft-versus-host-disease
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received…
- Trial name
- AGAVE-201 (NCT04710576)
- Testing
- Axatilimab
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Syndax Pharmaceuticals
Graves Disease
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
The purpose of this study is to assess the efficacy and safety of 24 weeks of treatment with batoclimab in adult participants with biochemically documented hyperthyroidism due to GD who have failed to achieve euthyroidism on…
- Trial name
- NCT05907668
- Testing
- IMVT-1401 (batoclimab)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Immunovant Sciences GmbH
End-stage Renal Disease, Malnutrition; Protein
Impact of IDPN on Nutrition Markers in Patients Receiving ICHD
Evaluate the impact of intradialytic parenteral nutrition (IDPN) compounded with Clinisol, Prosol, and/or Clinolipid on albumin levels and weight in patients with end-stage renal disease (ESRD) undergoing in-center hemodialysis.
- Trial name
- NCT05439174
- Testing
- Intradialytic Parenteral Nutrition
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Patient Care America
Healthy
A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men
The purpose of this study is to measure the blocking of [18F]JNJ-64511070 binding in the brain at the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the…
- Trial name
- NCT03693391
- Testing
- JNJ-64140284, Fluorine-18 Labeled [18F]-JNJ-64511070
- Where
- Belgium
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884
A Phase 1, single dose study with 4 cohorts of ascending doses and an optional Japanese cohort designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MEDI5884 in healthy volunteers
- Trial name
- NCT03001297
- Testing
- MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
To determine the activity of SCH 727965 in participants with breast cancer and in participants with nonsmall-cell lung cancer (NSCLC) compared to standard treatment.
- Trial name
- NCT00732810
- Testing
- SCH 727965, Capecitabine, Erlotinib
- Volunteers
- 97 people
- Sponsor
- Merck Sharp & Dohme LLC
Pain
A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China
1. To evaluate the tolerances of healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose 2.
- Trial name
- NCT03617510
- Testing
- Felbinac Trometamol Injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Patients With Advanced Solid Tumors
BAT7104 in Patients With Advanced Solid Tumours
This is a prospective multi-centre, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours in Australia.
- Trial name
- NCT05200013
- Testing
- BAT7104
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Bio-Thera Solutions
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
- Trial name
- ADvantage (NCT05149313)
- Testing
- Lebrikizumab
- Where
- 48 sites in Austria, Belgium and 6 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Heart Failure
C-Pulse IDE Feasibility Study- A Heart Assist System
The C-Pulse Feasibility Study is evaluating the safety and performance of a new product for the treatment of heart failure. The product is designed to help reduce the symptoms of heart failure and help patients function better…
- Trial name
- NCT00815880
- Testing
- C-Pulse™ (Implantable Counterpulsation Therapy)
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Nuwellis, Inc.
Colonoscopy
Evaluating the Effectiveness of Colon Preparation for Endoscopy Using Specialized Clinical Nutrition
This study is an open, prospective, comparative diagnostic studies aimed at improving the colonoscopy results, by optimizing the way of preparation for endoscopy
- Trial name
- NCT02714296
- Testing
- Nutridrink 200 ml, Nutridrink compact protein
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Nutricia Advanced
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
This open-label, single arm study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01326962
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Colon Cancer
Dose-Escalation Study in Advanced Colon Cancer Patients
This study is exploring different administration schedules (short versus prolonged infusion) to optimize the safety and efficacy profile of EPO906A (patupilone) in patients with pretreated advanced colon cancer.
- Trial name
- NCT00969046
- Testing
- EPO906 (patupilone)
- Where
- 6 sites in Czechia, France and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT05002127
- Testing
- Evorpacept (ALX148), Trastuzumab, Ramucirumab
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 127 people
- Sponsor
- ALX Oncology Inc.
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Healthy
Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers
This is a randomized, open-label, parallel design Phase I clinical trial to evaluate the safety/tolerability and pharmacokinetic of DWJ211 in healthy volunteers
- Trial name
- NCT04159961
- Testing
- DWJ211
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
High-risk Non-muscle Invasive Bladder Cancer
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2
- Trial name
- NCT06378242
- Testing
- Disitamab Vedotin for injection
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- RemeGen Co., Ltd.
Cancer
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0225 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.
- Trial name
- NCT00441870
- Testing
- EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate), 99mTC-EC20 (Folic acid-technetium 99m conjugate)
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Endocyte
Pancreatic Cancer
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new…
- Trial name
- NCT00401570
- Testing
- Volociximab, Gemcitabine
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.